Data mining on electronic health record databases for signal detection in pharmacovigilance: which events to monitor?
暂无分享,去创建一个
A. Pariente | A. Fourrier-Réglat | M. Molokhia | P. Coloma | G. Trifirò | J. Hippisley-Cox | J. van der Lei | M. Sturkenboom | J. Kors | N. Moore | A. Caputi | F. Salvo | G. Miremont-Salamé | G. Polimeni | M. Catania | A. David | Carlos Diaz Acedo
[1] R Revol Núñez,et al. [Aplastic anemia]. , 1970, Archivos Argentinos de Pediatria.
[2] Richard Platt,et al. Early adverse drug event signal detection within population‐based health networks using sequential methods: key methodologic considerations , 2009, Pharmacoepidemiology and drug safety.
[3] Richard Platt,et al. Active drug safety surveillance: a tool to improve public health , 2008, Pharmacoepidemiology and drug safety.
[4] Bruce M Psaty,et al. Benefits and risks of drug treatments: how to combine the best evidence on benefits with the best data about adverse effects. , 2008, JAMA.
[5] P. Noyce,et al. Hospital Admissions Associated with Adverse Drug Reactions: A Systematic Review of Prospective Observational Studies , 2008, The Annals of pharmacotherapy.
[6] M. Mockenhaupt,et al. Stevens-Johnson syndrome and toxic epidermal necrolysis induced by amifostine during head and neck radiotherapy. , 2008, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[7] V. Balan,et al. Inpatient Admissions for Drug-induced Liver Injury: Results from a Single Center , 2008, Digestive Diseases and Sciences.
[8] X. Vidal,et al. Epidemiology of aplastic anemia: a prospective multicenter study , 2008, Haematologica.
[9] N. Pannu,et al. An overview of drug-induced acute kidney injury , 2008, Critical care medicine.
[10] Miriam C J M Sturkenboom,et al. Adverse drug reaction‐related hospitalisations: a population‐based cohort study , 2008, Pharmacoepidemiology and drug safety.
[11] D. Pollock,et al. National surveillance of emergency department visits for outpatient adverse drug events in children and adolescents. , 2008, The Journal of pediatrics.
[12] S. Factor,et al. Failure of recognition of drug‐induced parkinsonism in the elderly , 2008, Movement disorders : official journal of the Movement Disorder Society.
[13] S. Dursun,et al. Neurological complications of psychiatric drugs: clinical features and management , 2008, Human psychopharmacology.
[14] C. Richards,et al. Medication Use Leading to Emergency Department Visits for Adverse Drug Events in Older Adults , 2007, Annals of Internal Medicine.
[15] M. Kulldorff,et al. Early detection of adverse drug events within population‐based health networks: application of sequential testing methods , 2007, Pharmacoepidemiology and drug safety.
[16] F. Martin,et al. Associations of delirium with in-hospital and in 6-months mortality in elderly medical inpatients. , 2007, Age and ageing.
[17] R. Aster,et al. Drug-induced immune thrombocytopenia. , 2007, The New England journal of medicine.
[18] Josip Car,et al. Trends in hospital admissions for adverse drug reactions in England: analysis of national hospital episode statistics 1998–2005 , 2007, BMC clinical pharmacology.
[19] W. Poewe,et al. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease , 2007, The Lancet Neurology.
[20] A. Melander,et al. Systematic Review of the Incidence and Characteristics of Preventable Adverse Drug Events in Ambulatory Care , 2007, The Annals of pharmacotherapy.
[21] D. Franciotti. Hospital admissions in Italy for liver and gastrointestinal diseases in the period 1999–2002: an epidemiological study , 2007, European journal of gastroenterology & hepatology.
[22] E. Růžička,et al. Low incidence of restrictive valvulopathy in patients with Parkinson's disease on moderate dose of pergolide , 2007, Journal of Neurology.
[23] F. Andersohn,et al. Systematic Review: Agranulocytosis Induced by Nonchemotherapy Drugs , 2007, Annals of Internal Medicine.
[24] Mark McClellan,et al. Drug safety reform at the FDA--pendulum swing or systematic improvement? , 2007, The New England journal of medicine.
[25] J. Gottschall,et al. One center's experience: the serology and drugs associated with drug‐induced immune hemolytic anemia—a new paradigm , 2007, Transfusion.
[26] Meredith Wadman,et al. Experts call for active surveillance of drug safety , 2007, Nature.
[27] J. Thundiyil,et al. Evolving epidemiology of drug-induced seizures reported to a poison control center system , 2007, Journal of Medical Toxicology.
[28] F. Hanefeld,et al. Valproic acid-induced pancreatitis: 16 new cases and a review of the literature , 2007, Journal of Gastroenterology.
[29] M. Matthews,et al. Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy. , 2007, Clinical therapeutics.
[30] S. Gentile. Extrapyramidal Adverse Events Associated With Atypical Antipsychotic Treatment of Bipolar Disorder , 2007, Journal of clinical psychopharmacology.
[31] S. Gentile. Nontricyclic antidepressants - Predictors of nonadherence , 2007 .
[32] A. Antonini,et al. Valvular heart disease and the use of dopamine agonists for Parkinson's disease. , 2007, The New England journal of medicine.
[33] I. Boyd,et al. Risk Factors for Rhabdomyolysis with Simvastatin and Atorvastatin , 2006, Drug safety.
[34] J. Montastruc,et al. The nature of the scientific evidence leading to drug withdrawals for pharmacovigilance reasons in France , 2006, Pharmacoepidemiology and drug safety.
[35] D. Pollock,et al. National surveillance of emergency department visits for outpatient adverse drug events. , 2006, JAMA.
[36] N. Young,et al. Current concepts in the pathophysiology and treatment of aplastic anemia. , 2006, Blood.
[37] R. Mullins,et al. 2. Anaphylaxis: diagnosis and management , 2006, The Medical journal of Australia.
[38] Manfred Hauben,et al. Data mining in pharmacovigilance: lessons from phantom ships , 2006, European Journal of Clinical Pharmacology.
[39] Anandi V Law,et al. Adverse Drug Reactions Among Children Over a 10-Year Period , 2006, Pediatrics.
[40] Robert L Davis,et al. FDA drug prescribing warnings: is the black box half empty or half full? , 2006, Pharmacoepidemiology and drug safety.
[41] Jerry Avorn,et al. Evaluating drug effects in the post-Vioxx world: there must be a better way. , 2006, Circulation.
[42] Borje Darpo,et al. Clinical Evaluation of QT/QTc Prolongation and Proarrhythmic Potential for Nonantiarrhythmic Drugs: The International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use E14 Guideline , 2006, Journal of clinical pharmacology.
[43] N. Scheinfeld. Imatinib mesylate and dermatology part 2: a review of the cutaneous side effects of imatinib mesylate. , 2006, Journal of drugs in dermatology : JDD.
[44] J. Vandenbroucke. What is the best evidence for determining harms of medical treatment? , 2006, Canadian Medical Association Journal.
[45] Miriam C.J.M. Sturkenboom,et al. Adverse Drug Reaction-Related Hospitalisations , 2006, Drug safety.
[46] P. Waller,et al. Comparison of hospital episodes with 'drug-induced' disorders and spontaneously reported adverse drug reactions. , 2006, British journal of clinical pharmacology.
[47] D. Madigan,et al. The role of data mining in pharmacovigilance , 2005, Expert opinion on drug safety.
[48] M. Vray,et al. The respective roles of controlled clinical trials and cohort monitoring studies in the pre- and postmarketing assessment of drugs. , 2005, Therapie.
[49] A. Puech,et al. Place relative des essais cliniques comparatifs et des suivis de cohorte dans l’évaluation préet post-AMM des médicaments , 2005 .
[50] D. Wysowski,et al. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions. , 2005, Archives of internal medicine.
[51] G. Trifirò,et al. Adverse drug events in emergency department population: a prospective Italian study , 2005, Pharmacoepidemiology and drug safety.
[52] X. Vidal,et al. Population-based drug-induced agranulocytosis. , 2005, Archives of internal medicine.
[53] N. Yawalkar. Drug-induced exanthems. , 2005, Toxicology.
[54] J. Avorn,et al. A review of uses of health care utilization databases for epidemiologic research on therapeutics. , 2005, Journal of clinical epidemiology.
[55] J. Lexchin. Drug withdrawals from the Canadian market for safety reasons, 1963–2004 , 2005, Canadian Medical Association Journal.
[56] P. Waller,et al. Hospital admissions for 'drug-induced' disorders in England: a study using the Hospital Episodes Statistics (HES) database. , 2005, British journal of clinical pharmacology.
[57] M. Egger,et al. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis , 2004, The Lancet.
[58] N. Winick,et al. Acute methotrexate neurotoxicity: findings on diffusion-weighted imaging and correlation with clinical outcome. , 2004, AJNR. American journal of neuroradiology.
[59] S. Deitcher,et al. The risk of venous thromboembolic disease associated with adjuvant hormone therapy for breast carcinoma , 2004, Cancer.
[60] M. Pirmohamed,et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients , 2004, BMJ : British Medical Journal.
[61] E. Keohane. Acquired Aplastic Anemia , 2004, American Society for Clinical Laboratory Science.
[62] J. Brien,et al. Frequency and characteristics of hospital admissions associated with drug-related problems in paediatrics. , 2004, British journal of clinical pharmacology.
[63] Lehana Thabane,et al. Application of data mining techniques in pharmacovigilance. , 2003, British journal of clinical pharmacology.
[64] A. Berghöfer,et al. The Antisuicidal and Mortality-Reducing Effect of Lithium Prophylaxis: Consequences for Guidelines in Clinical Psychiatry , 2003, Canadian journal of psychiatry. Revue canadienne de psychiatrie.
[65] G. Sachs. Unmet Clinical Needs in Bipolar Disorder , 2003, Journal of clinical psychopharmacology.
[66] Nicholas Moore,et al. Biases affecting the proportional reporting ratio (PRR) in spontaneous reports pharmacovigilance databases: the example of sertindole , 2003, Pharmacoepidemiology and drug safety.
[67] B. Alldredge,et al. Risk of seizures associated with psychotropic medications: emphasis on new drugs and new findings , 2003, Expert opinion on drug safety.
[68] Joshua Borus,et al. Adverse drug events in ambulatory care. , 2003, The New England journal of medicine.
[69] Robert W. Platt,et al. Delirium in Older Emergency Department Patients Discharged Home: Effect on Survival , 2003, Journal of the American Geriatrics Society.
[70] T. Gillessen,et al. Iatrogenic and toxic myopathies , 2003, Muscle & nerve.
[71] M. Cesari,et al. Adverse Drug Reactions as Cause of Hospital Admissions: Results from the Italian Group of Pharmacoepidemiology in the Elderly (GIFA) , 2002, Journal of the American Geriatrics Society.
[72] A. Bate,et al. Data-mining analyses of pharmacovigilance signals in relation to relevant comparison drugs , 2002, European Journal of Clinical Pharmacology.
[73] P. Hillon,et al. Incidence of drug‐induced hepatic injuries: A French population‐based study , 2002, Hepatology.
[74] Sebastian Schneeweiss,et al. Admissions caused by adverse drug events to internal medicine and emergency departments in hospitals: a longitudinal population-based study , 2002, European Journal of Clinical Pharmacology.
[75] C. Nzerue,et al. How to prevent, recognize, and treat drug-induced nephrotoxicity. , 2002, Cleveland Clinic journal of medicine.
[76] R. Shah. Drug‐induced prolongation of the QT interval: regulatory dilemmas and implications for approval and labelling of a new chemical entity , 2002, Fundamental & clinical pharmacology.
[77] K. Lechner,et al. Management of adult immune thrombocytopenia. , 2001, Reviews in clinical and experimental hematology.
[78] D J Graham,et al. The role of databases in drug postmarketing surveillance , 2001, Pharmacoepidemiology and drug safety.
[79] S. Schneeweiss,et al. First results from an intensified monitoring system to estimate drug related hospital admissions. , 2001, British journal of clinical pharmacology.
[80] J. Vandenbroucke,et al. Oral contraceptives and the risk of venous thrombosis. , 2001, The New England journal of medicine.
[81] B. Bannwarth,et al. [Drug-induced and toxic myopathies]. , 2001, La Revue du praticien.
[82] S. Shapiro,et al. Epidemiological assessment of drug-induced disease , 2000, The Lancet.
[83] P. Chyka,et al. How many deaths occur annually from adverse drug reactions in the United States? , 2000, The American journal of medicine.
[84] P Smyth,et al. Statistical Methods in Medical Research Data Mining: Data Analysis on a Grand Scale? , 2022 .
[85] N. Moore,et al. Adverse drug reactions in a department of systemic diseases-oriented internal medicine: prevalence, incidence, direct costs and avoidability , 2000, European Journal of Clinical Pharmacology.
[86] F. Haramburu,et al. Admissions to hospital caused by adverse drug reactions: cross sectional incidence study , 2000, BMJ : British Medical Journal.
[87] P. Padfield,et al. Renal , 1999, Diabetic medicine : a journal of the British Diabetic Association.
[88] B. Wiholm,et al. Drug‐attributed anaphylaxis , 1998, Pharmacoepidemiology and drug safety.
[89] Munir Pirmohamed,et al. Fortnightly review: Adverse drug reactions , 1998 .
[90] D. Bonn,et al. Adverse drug reactions remain a major cause of death , 1998, The Lancet.
[91] P. Corey,et al. Incidence of Adverse Drug Reactions in Hospitalized Patients , 2012 .
[92] I. Edwards,et al. Adverse drug reactions: finding the needle in the haystack , 1997, BMJ.
[93] L. Hughes-Davies,et al. Severe adverse cutaneous reactions to drugs. , 1995, The New England journal of medicine.
[94] J. Bigby. Harrison's Principles of Internal Medicine , 1988 .
[95] B. Jakubski. [Acute toxic renal failure]. , 1983, Wiadomosci lekarskie.
[96] Thomas F. DeRosa,et al. PSYCHIATRIC , 1970 .
[97] L. Naldi,et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. , 2008, The Journal of investigative dermatology.
[98] J. Roujeau,et al. Drug-Induced Skin, Nail and Hair Disorders , 2007, Drug safety.
[99] Munir Pirmohamed,et al. Adverse drug reactions in hospitals: a narrative review. , 2007, Current drug safety.
[100] Ayman A El Menyar. Drug-induced myocardial infarction secondary to coronary artery spasm in teenagers and young adults. , 2006, Journal of postgraduate medicine.
[101] R. Meyboom,et al. Drug-Induced Immune Thrombocytopenia , 2004, Drug safety.
[102] M. Arné-Bès. Neuropathies médicamenteuses: mise a jour récente des données (1996 a 2003). , 2004 .
[103] Giuseppe Curigliano,et al. Drug-induced prolongation of the QT interval. , 2004, The New England journal of medicine.
[104] M. Lindquist,et al. Assessing the Impact of Drug Safety Signals from the WHO Database Presented in ‘SIGNAL’ , 2003, Drug safety.
[105] M. Lindquist,et al. Signal Selection and Follow-Up in Pharmacovigilance , 2002, Drug safety.
[106] I. Edwards. The Accelerating Need for Pharmacovigilance , 2000, Journal of the Royal College of Physicians of London.
[107] R. Baldessarini,et al. Reduced suicide risk during lithium maintenance treatment. , 2000, The Journal of clinical psychiatry.
[108] Edwards Ir. The accelerating need for pharmacovigilance. , 2000 .
[109] J. George,et al. Drug-induced thrombocytopenia: a systematic review of published case reports. , 1998, Annals of internal medicine.
[110] S. R. Fine,et al. ADVERSE DRUG REACTIONS , 2009, BMJ : British Medical Journal.